Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 30, 2022 - Issue 4
Submit an article Journal homepage
241
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia

Parsa Mehraban FarDepartment of Ophthalmology, Queen’s University, Kingston, Ontario, Canada
, BHSc,
Jacob RulloDepartment of Ophthalmology, Queen’s University, Kingston, Ontario, Canada
, MD, PhD,
James FarmerDepartment of Ophthalmology, Queen’s University, Kingston, Ontario, Canada
, MD &
Todd UrtonDepartment of Ophthalmology, Queen’s University, Kingston, Ontario, CanadaCorrespondence[email protected]
, MD
Pages 1005-1008 | Received 27 Jan 2020, Accepted 20 Oct 2020, Published online: 04 Feb 2021

References

  • Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018;131(4):379–386. doi:10.1182/blood-2017-08-764712.
  • O’Brien S, Hillmen P, Coutre S, et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(10):648–657.e15. doi:10.1016/j.clml.2018.06.016.
  • Kolomeyer AM, Hwang CK, Kim BJ. Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature. J Med Case Rep. 2018;12(1):349. doi:10.1186/s13256-018-1822-9.
  • Saenz-de-Viteri M, Cudrnak T. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib. Leuk Lymphoma. 2019;60(3):842–844. doi:10.1080/10428194.2018.1508673.
  • Byrd JC, O’Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(13):1277–1279. doi:10.1056/NEJMc1309710.
  • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154.
  • Kunkler AL, Binkley EM, Mantopoulos D, et al. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefe’s Arch Clin Exp Ophthalmol. 2019;257(8):1771–1781. doi:10.1007/s00417-019-04337-8.
  • Tyagi P, Santiago C. New features in MEK retinopathy. BMC Ophthalmol. 2018;18(S1):221. doi:10.1186/s12886-018-0861-8.
  • Peterson JL, Phelps ED, Doll MA, Schaal S, Ceresa BP. The role of endogenous epidermal growth factor receptor ligands in mediating corneal epithelial homeostasis. Investig Ophthalmol Vis Sci. 2014;55(5):2870–2880. doi:10.1167/iovs.13-12943.
  • Jun G, Guo H, Klein BEK, et al. EPHA2 is associated with age-related cortical cataract in mice and humans. van Heyningen V, ed. PLoS Genet. 2009;5(7):e1000584. doi:10.1371/journal.pgen.1000584.
  • Kondo K, Shaim H, Thompson PA, et al. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia. 2018;32(4):960–970. doi:10.1038/leu.2017.304.
  • Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–2549. doi:10.1182/blood-2013-06-507947.
  • U.S. Food and Drug Administration. Pharmacology review; 2013. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205552Orig2s000PharmR.pdf
  • U.S. Food and Drug Administration. Highlights of prescribing information; 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205552s030,210563s006lbl.pdf
  • Blomquist PH. Ocular complications of systemic medications. Am J Med Sci. 2011;342:62–69. doi:10.1097/MAJ.0b013e3181f06b21.
  • Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A, Singh A. Checkpoint inhibitor-induced uveitis: a case series. Graefe’s Arch Clin Exp Ophthalmol. 2018;256(1):187–191. doi:10.1007/s00417-017-3835-2.
  • Noble CW, Gangaputra SS, Thompson IA, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. Published online April 23 2019;1–6. doi:10.1080/09273948.2019.1583347.
  • Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768. doi:10.1200/JCO.2017.77.6385.
  • Liu X, Wang Z, Zhao C, et al. Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thorac Cancer. 2020;11(3):810–818. doi:10.1111/1759-7714.13327.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.